Browse all 652 ETFs by category, no search needed
Global 186
US market 62
Country 93
Core UCITS 15
Sector 103
Style & factor 111
Theme 45
Dividend 37
ARK Genomic Revolution (ARKG)
Look-through valuation · Theme · Expense ratio 0.75 % · ISIN US00214Q3020
Price history (since 2014)
Monthly close since 2014. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| 10X Genomics Inc TXG | 9.2 % | −69.0 % | 65 |
| Twist Bioscience Corp TWST | 9.0 % | n/a | n/a |
| Tempus AI, Inc. Class A Common Stock TEM | 8.2 % | n/a | n/a |
| Crispr Therapeutics AG CRSP | 5.4 % | −66.1 % | 28 |
| Absci Corp ABSI | 5.1 % | n/a | n/a |
| Personalis Inc PSNL | 5.0 % | n/a | n/a |
| Illumina Inc ILMN | 4.7 % | +9.0 % | 81 |
| Guardant Health Inc GH | 4.6 % | n/a | n/a |
| Natera Inc NTRA | 4.6 % | −94.4 % | 40 |
| CareDx Inc CDNA | 4.4 % | −78.7 % | 71 |
| Eli Lilly and Company LLY | 3.5 % | −35.8 % | 67 |
| Beam Therapeutics Inc BEAM | 3.2 % | −59.4 % | 46 |
| Recursion Pharmaceuticals Inc RXRX | 3.1 % | −80.5 % | 22 |
| Schrodinger Inc SDGR | 3.0 % | −72.6 % | 60 |
| Compass Pathways Plc CMPS | 2.5 % | n/a | n/a |
| Veracyte Inc VCYT | 2.4 % | +12.3 % | 72 |
| Adaptive Biotechnologies Corp ADPT | 2.3 % | n/a | n/a |
| Butterfly Network Inc BFLY | 2.0 % | n/a | n/a |
| Nurix Therapeutics Inc NRIX | 1.8 % | n/a | n/a |
| Ionis Pharmaceuticals Inc IONS | 1.8 % | n/a | n/a |
| Intellia Therapeutics Inc NTLA | 1.7 % | −81.8 % | 32 |
| GeneDx Holdings Corp. WGS | 1.7 % | −85.2 % | 48 |
| Arcturus Therapeutics Holdings Inc ARCT | 1.7 % | −46.1 % | 40 |
| Alamar Biosciences, Inc. Common Stock ALMR | 1.5 % | n/a | n/a |
| Pacific Biosciences of California PACB | 1.4 % | n/a | n/a |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 32 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +76.9 % below FV
- 2 MCHI iShares MSCI China ETF +41.9 % below FV
- 3 ITB iShares U.S. Home Construction ETF +37.1 % below FV
- 4 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +32.2 % below FV
- 5 VOX Vanguard Communication Services Index Fund ETF Shares +21.5 % below FV
- 6 XLC Communication Services Select Sector SPDR® Fund +20.6 % below FV
- 7 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +19.1 % below FV
- 8 FDNI First Trust Dow Jones International Internet ETF +15.2 % below FV
- 9 SHRY First Trust Bloomberg Shareholder Yield ETF +14.6 % below FV
- 10 TAN Invesco Solar ETF +14.5 % below FV
Frequently asked about ARKG
Is ARKG overvalued?
How do you calculate the fair value of an ETF?
Which stocks drive the valuation of ARKG?
What is the expense ratio of ARKG?
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives ARK Genomic Revolution ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Oct 15, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.